- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Endocrinology
Volume 2013 (2013), Article ID 374858, 5 pages
Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide
1Department of Internal Medicine 4, Faculty of Medicine, L. Pasteur University Hospital, P. J. Šafárik University in Košice, 041 90 Košice, Slovakia
2Department of Medical Biology, Faculty of Medicine, P. J. Šafárik University in Košice, 040 66 Košice, Slovakia
Received 4 December 2012; Accepted 20 January 2013
Academic Editor: Ewan Pearson
Copyright © 2013 Martin Javorský et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- F. M. Gribble and F. Reimann, “Sulphonylurea action revisited: the post-cloning era,” Diabetologia, vol. 46, no. 7, pp. 875–891, 2003.
- S. L. Shyng and C. G. Nichols, “Octameric stoichiometry of the channel complex,” Journal of General Physiology, vol. 110, no. 6, pp. 655–664, 1997.
- J. C. Florez, N. Burtt, P. I. W. De Bakker et al., “Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region,” Diabetes, vol. 53, no. 5, pp. 1360–1368, 2004.
- V. Lang, M. Fatehi, and P. E. Light, “Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A,” Pharmacogenetics and Genomics, vol. 22, no. 3, pp. 206–214, 2012.
- Y. Feng, G. Mao, X. Ren et al., “Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients,” Diabetes Care, vol. 31, no. 10, pp. 1939–1944, 2008.
- M. Javorsky, L. Klimcakova, Z. Schroner, et al., “KCNJ11 gene E23K variant and therapeutic response to sulfonylureas,” European Journal of Internal Medicine, vol. 23, no. 3, pp. 245–249, 2012.
- S. F. A. Grant, G. Thorleifsson, I. Reynisdottir et al., “Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes,” Nature Genetics, vol. 38, no. 3, pp. 320–323, 2006.
- Y. Tong, Y. Lin, Y. Zhang et al., “Association between TCF7L2 gene polymorphisms and susceptibility to Type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis,” BMC Medical Genetics, vol. 10, article 15, 2009.
- J. C. Florez, K. A. Jablonski, N. Bayley et al., “TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program,” The New England Journal of Medicine, vol. 355, no. 3, pp. 241–250, 2006.
- R. Saxena, L. Gianniny, N. P. Burtt et al., “Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals,” Diabetes, vol. 55, no. 10, pp. 2890–2895, 2006.
- E. R. Pearson, L. A. Donnelly, C. Kimber et al., “Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study,” Diabetes, vol. 56, no. 8, pp. 2178–2182, 2007.
- Z. Schroner, M. Javorsky, R. Tkacova et al., “Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 13, no. 1, pp. 89–91, 2011.
- A. Holstein, M. Hahnl, A. Körner, M. Stumvoll, and P. Kovacs, “TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes,” BMC Medical Genetics, vol. 24, pp. 12–30, 2011.
- S. Seino, “Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea,” Diabetologia, vol. 55, no. 8, pp. 2096–2108, 2012.
- M. Winkler, D. Stephan, S. Bieger, P. Kühner, F. Wolff, and U. Quast, “Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 2, pp. 701–708, 2007.
- American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 29, Supplement 1, pp. S43–S48, 2006.
- Z. Liu and J. F. Habener, “Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation,” Journal of Biological Chemistry, vol. 283, no. 13, pp. 8723–8735, 2008.
- F. Preitner, M. Ibberson, I. Franklin et al., “Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors,” Journal of Clinical Investigation, vol. 113, no. 4, pp. 635–645, 2004.
- T. Shibasaki, H. Takahashi, T. Miki et al., “Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19333–19338, 2007.
- C. L. Zhang, M. Katoh, T. Shibasaki et al., “The cAMP sensor epac2 is a direct target of antidiabetic sulfonylurea drugs,” Science, vol. 325, no. 5940, pp. 607–610, 2009.
- D. T. Villareal, H. Robertson, G. I. Bell et al., “TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action,” Diabetes, vol. 59, no. 2, pp. 479–485, 2010.
- A. Patel, S. MacMahon, J. Chalmers et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008.
- G. Schernthaner, A. Grimaldi, U. Di Mario et al., “Guide study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients,” European Journal of Clinical Investigation, vol. 34, no. 8, pp. 535–542, 2004.